This mechanism is important as EZH2 inhibition therapy has been suggested to promote the response to immunotherapy in pre-clinical models [50] and is being investigated in several clinical trials for non-small cell lung cancer (NCT05467748, NCT06644768, NCT06022757, NCT05023655). The gene discussed is EZH2; the disease is non-small cell lung carcinoma.